A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma

A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma - A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026438

Enrollment

Registered

2017-03-10

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

Hypofractionated external-beam radiotherapy (30 Gy in 10 fractions) with concurrent S-1 (60 mg/m2) was delivered 5 days/week for 2 weeks prior to pancreatectomy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: PDAC R and BR PS 0-1 Age 20-85 adequate organ function

Exclusion criteria

Exclusion criteria: Concurrent active malignancy Uncontrolled infection Unable to receive S1 History of Severe allergy Chemotherapy Radiation Myocardial infarction Unstable angina Interstitial pneumonia Severe emphysema fibroid lung severe emphysema

Design outcomes

Primary

Measure	Time frame
R0 resection rate Pathological response Disease free survival	—

Secondary

Measure	Time frame
Toxicities (CTCAE v4.0) Overall survival	—

Countries

Japan

Contacts

Public ContactKeiichi Okano

Kagawa University Gastroenterological Surgery

kokano@med.kagawa-u.ac.jp0878912438

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026